CJC-1295
Growth Hormone Releasing Peptide - GHRH analog studied for sustained GH signaling.
CJC-1295 (without DAC) is a modified growth-hormone-releasing hormone analog, studied for its role in stimulating GH and IGF-1 signaling in endocrine research.
The no-DAC form of CJC-1295 (modified GRF 1-29) is studied for its more pulsatile GH profile, and it is frequently paired with a ghrelin-receptor secretagogue to study the two GH-release mechanisms together. It provides a shorter-acting counterpart to the DAC version.
CJC-1295 specifications
- CAS number
- 863288-34-0
- Molecular formula
- C152H252N44O42
- Molecular weight
- 3368.7 g/mol
- Sequence
- Modified GHRH(1-29) analog
- Residues
- 29 residues (mod GRF 1-29)
- Presentation
- Lyophilized powder
- Documented purity
- 99.68% by HPLC
- Available sizes
- 5mg ($40)
- Archived COA lots
- 5
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- GHRH signaling - Studied for potentiation of pulsatile GH and downstream IGF-1 activity.
Reported mechanisms in the literature
- GHRH signaling - A modified GHRH(1-29) analog studied for potentiation of pulsatile GH and downstream IGF-1 signaling in endocrine research. (Teichman et al.)
What CJC-1295 is researched for
- GHRH signaling - Studied for potentiation of pulsatile GH and downstream IGF-1 signaling. (Teichman et al.)
- IGF-1 response - Investigated for its IGF-1 response profile in endocrine-research models. (Preclinical literature)
CJC-1295 certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| CJC-101926-5 | 22 Oct 2026 | 5mg | ILS Laboratories | 99.89% | Confirmed (HPLC retention time) | COA PDF |
| FD-2605110189 | 11 May 2026 | 5mg | Freedom Diagnostics | 99.72% | Confirmed (LC-MS/MS) | COA PDF |
| 700001 | 20 Feb 2026 | 5mg | Freedom Diagnostics | 99.92% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2602180084 | 18 Feb 2026 | 5mg | Freedom Diagnostics | 99.92% | Confirmed (LC-MS/MS) | COA PDF |
| CND509032025-J01 | 10 Sep 2025 | 5mg | Freedom Diagnostics | 99.29% | Confirmed (LC-MS/MS) | COA PDF |
Published literature on CJC-1295
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
CJC-1295 frequently asked questions
What is CJC-1295 (no DAC)?
A modified growth-hormone-releasing hormone analog (mod GRF 1-29), studied for stimulating GH and IGF-1 signaling in endocrine research.
Is it approved for human use?
No. It is a research material only, with preclinical data. It is not a medicine or supplement.
How does it differ from the DAC version?
Without the drug-affinity complex it has a shorter half-life, so researchers study it for more pulsatile GHRH signaling.
Documented to 99.68% purity by HPLC · third-party COA every lot · from $40 · For laboratory research use only.
Related Growth Hormone compounds
- Tesamorelin - GHRH analog studied for growth-hormone-axis research.
- TESA / IPA Blend - Tesamorelin + Ipamorelin co-formulated GH-research blend.
- Ipamorelin - Selective GH secretagogue studied for receptor-selective GH release.
- CJC-1295 DAC - Long-acting GHRH analog with drug-affinity complex.
- Sermorelin - GHRH(1-29) fragment studied for GH-axis research.
- CJC / IPA Blend - CJC-1295 + Ipamorelin co-formulated GH-research blend.